ClinicaliQ Trial Snapshot
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants — Recruiting • Phase I • NCT07312851.
- Andexanet alfa dosing study examining how it interacts with subsequent enoxaparin treatment in healthy volunteers.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to characterize andexanet posology and interaction between andexanet and enoxaparin post infusion in healthy participants. Conditions: Healthy Participants Interventions: Andexanet alfa, Rivaroxaban, Apixaban, Enoxaparin, Placebo Lead Sponsor: AstraZeneca Planned Enrollment: 186 participants